Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma-Reference-Cited by-同舟云学术

Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma

Published:2007-10 Issue:5 Volume:22 Page:684-691
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Emmanouilides Christos¹,Witzig Thomas E.²,Wiseman Gregory A.²,Gordon Leo I.³,Wang Hua⁴,Schilder Russell⁵,Saville M. Wayne⁴,Flinn Ian⁶,Molina Arturo⁴

Affiliation:

1. Division of Hematology/Oncology, University of California, Los Angeles, CA

2. Division of Hematology, Mayo Clinic, Rochester, MN

3. Division of Hematology/Oncology, Northwestern University Medical School, Chicago, IL

4. Global Medical Affairs, Biogen Idec Inc., San Diego, CA

5. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA

6. Hematologic Malignancies Research, Sarah Cannon Research Institute, Nashville, TN

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2007.359

Reference29 articles.

1. Cancer Statistics, 2007

2. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

3. Radioimmunotherapy for lymphoma

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates;Cancers;2023-09-13

2. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study;Annals of Hematology;2023-03-30

3. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies;Journal of Fungi;2021-03-05

4. How we treat mature B-cell neoplasms (indolent B-cell lymphomas);Journal of Hematology & Oncology;2021-01-06

5. Risk of infection associated with targeted therapies for solid organ and hematological malignancies;Therapeutic Advances in Infectious Disease;2021-01